KRK.WAR Krka d. d

Healthcare Pharmaceuticals Warsaw Stock Exchange
1,114 PLN
Close of Oct 29, 2026
789.17 1,180
Market cap
PLN 33.7B
P/E
19.0x
P/B
2.93x
ROE
19.9%
Dividend yield
3.54%
Fundamental score
3.2/5

Ratios use the latest price and the current fiscal year annualized from 2 quarters up to Jun 2026.

Is KRK.WAR undervalued?

Graham number
Price1,114
Graham value706.76
Premium57.6%

KRK.WAR trades 57.6% above its Graham number.

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

Krka d. d fundamental analysis

15 of 22 checks passed

ROE 1/2

Moderate return on equity (19.9%), between 10% and 20%.

ROA 1/1

Return on assets (15.6%) is above the industry median (3.8%).

Profit Consistency 2/2

Profitable for 10 consecutive years.

Earnings Growth 5Y 1/1

Earnings per share grew over the past 5 years.

Earnings Acceleration 1/1

Last year's EPS growth (11.7%) is above the 5-year average (6.9% a year).

Earnings Growth vs Industry 0/1

Last year's EPS growth (11.7%) is below the industry median (14.7%).

Revenue Growth 1/2

Revenue grew 5.9% a year over the past 3 years.

Short-term Liquidity 1/1

Current assets cover short-term liabilities.

Long-term Liabilities 1/1

Current assets cover long-term liabilities.

Debt to Equity 2/2

Low debt to equity (0.7%), 40% or less.

Debt Trend 0/1

Debt to equity has risen over the past 5 years.

Debt Coverage 1/1

Operating cash flow covers 20% of total debt.

Interest Coverage 1/1

EBIT is 51.8x against interest expense, well covered.

PE vs Market 0/1

PE (19.0x) is above the market median (11.6x).

PE vs Industry 0/1

PE (19.0x) is above the industry median (16.6x).

PBV 0/1

Price to book (2.9x) is above the industry median (1.5x).

Graham Number 0/1

The price is above the Graham number (PE x PB = 55.9, limit 22.5).

PEG 0/1

PEG on 5-year earnings growth is 2.75, above 1.

Dividend Yield 1/2

Dividend yield (3.3%) is above the bottom 25% of dividend payers in the market.

Dividend Stability 2/2

Dividends paid without a cut of more than 10% for 11 years.

Dividend Growth 1/1

Dividends paid grew over the past 5 years.

Payout Ratio 1/1

Payout ratio is 62.5%, covered by earnings.

Each check is worth 1 or 2 points by how much it says about the quality of the company. The score is the share of points earned, out of 5. Ask AI to explain this score

Krka d. d stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About Krka d. d

Krka, d. d., a generic pharmaceutical company, develops, produces, markets, and sells prescription pharmaceuticals, non-prescription products, and animal health products in Slovenia, South-East Europe, East Europe, Central Europe, West Europe, and internationally. The company offers prescription pharmaceuticals for cardiovascular, central nervous system, gastrointestinal tract, pain, diabetes, and other therapeutic areas. It also provides non-prescription products for cough,…

Full company profile